Elevated Interleukin-17 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
- *Corresponding Author:
- Weiqi Lu
Department of General Surgery
Zhongshan Hospital, Shanghai, China
E-mail: [email protected]
Received date April 29, 2016; Accepted date June 15, 2016; Published date June 22, 2016
Citation: Chen C, Shao Y, Wu X, Huang C, Lu W (2016) Elevated Interleukin-17 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Biochem Physiol 5:206. doi: 10.4172/2168-9652.1000206
Copyright: © 2016 Chen C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Interleukin (IL)-17 is a newly described T cell-derived inflammatory cytokine. Recent studies have shown that inflammatory cytokines play important roles in the pathogenesis of type 2 diabetes mellitus (DM). However, whether IL-17 plays a prominent role in type 2 DM remains unclear. Here we measured serum concentrations of IL-17, and mRNA expression of IL-17 and its transcription factor RORγt in peripheral blood mononuclear cells (PBMC) from 30 patients with newly diagnosed type 2 DM and 20 healthy subjects. Results have shown that serum levels of IL-17 were significantly higher in patients than in healthy subjects (10.44 ± 6.47 vs. 2.99 ± 1.68 pg/mL, P<0.01); and mRNA levels of IL-17 and its transcript factor RORγt were also upregulated in PBMC from patients (P<0.001). Further, IL-17 mRNA expression was correlated with TNF-α mRNA expression in PBMC from patients (r=0.6988, P<0.001). These results indicated that IL-17 might contribute to the inflammation process in type 2 diabetes as an inflammation factor.